Children's Cancer Group (CCG) initiatives in childhood acute lymphoblastic leukemia

被引:0
|
作者
Gaynon, PS [1 ]
Bostrom, BC
Reaman, GH
Sather, HN
Trigg, ME
Tubergen, DG
Uckun, FM
机构
[1] Univ Wisconsin, Med Ctr, Madison, WI 53706 USA
[2] Minneapolis Childrens Hlth Ctr, Minneapolis, MN USA
[3] Childrens Natl Med Ctr, Washington, DC 20010 USA
[4] Univ So Calif, Sch Med, Los Angeles, CA USA
[5] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA
[6] MD Anderson Cancer Ctr, Houston, TX USA
[7] Univ Minnesota, Med Ctr, Biotherapy Program, Roseville, MN USA
关键词
childhood acute lymphoblastic leukemia; early response to therapy; postinduction intensification;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Childhood acute lymphoblastic leukemia (ALL) is the single most common malignancy in children([1]) and its incidence is increasing.([2]) Despite the signal progress to date,([3]) the absolute number of children with ALL who have relapses still exceeds the number of children with newly diagnosed acute myeloid leukemia, medulloblastoma and osteosarcoma. In the Children's Cancer Group (CCG) experience, approximately one-half of relapses still derive from the two-thirds of patients with favorable presenting features and one-half of relapses from the one-third of patients with unfavorable presenting features. Childhood ALL continues to contribute greatly to the overall morbidity and mortality of childhood cancer.
引用
收藏
页码:99 / 114
页数:16
相关论文
共 50 条
  • [21] Treatment of relapsed acute lymphoblastic leukemia in children: an observational study of the Japan Children's Cancer Group
    Goto, Hiroaki
    Kada, Akiko
    Ogawa, Chitose
    Nishiuchi, Ritsuo
    Yamanaka, Junko
    Iguchi, Akihiro
    Nishi, Masanori
    Sakaguchi, Kimiyoshi
    Kumamoto, Tadashi
    Mochizuki, Shinji
    Ueki, Hideaki
    Kosaka, Yoshiyuki
    Saito, Akiko M.
    Toyoda, Hidemi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024,
  • [22] Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)
    Schultz, Kirk R.
    Pullen, D. Jeanette
    Sather, Harland N.
    Shuster, Jonathan J.
    Devidas, Meenakshi
    Borowitz, Michael J.
    Carrol, Andrew J.
    Heerema, Nyla A.
    Rubnitz, Jeff Rey E.
    Loh, Mignon L.
    Raetz, Elizabeth A.
    Winick, Naomi J.
    Hunger, Stephen P.
    Carroll, William L.
    Gaynon, Paul S.
    Camitta, Bruce M.
    BLOOD, 2007, 109 (03) : 926 - 935
  • [23] Treatment of high risk T-cell acute lymphoblastic leukemia (TALL): Comparison of recent experience of the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG).
    Seibel, NL
    Asselin, BL
    Nachman, JB
    Steinherz, P
    Camitta, B
    Devidas, M
    Sather, HN
    BLOOD, 2004, 104 (11) : 195A - 196A
  • [24] Clinical characteristics and treatment outcome of children with acute lymphoblastic leukemia (ALL) and Down syndrome (DS): Follow-up of the children's cancer group (CCG) cohort.
    Bhatia, S
    Sather, HN
    Trigg, M
    Gaynon, PS
    Robison, LL
    James, WA
    BLOOD, 2001, 98 (11) : 719A - 719A
  • [25] Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's oncology group study CCG-1952
    Malempati, Suman
    Gaynon, Paul S.
    Sather, Harland
    La, Mei K.
    Stork, Linda C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (36) : 5800 - 5807
  • [26] Long-term results of children with acute myeloid leukemia: A report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891
    Smith, FO
    Alonzo, T
    Gerbing, RB
    Woods, WG
    Arceci, R
    LEUKEMIA, 2005, 19 (12) : 2054 - 2062
  • [27] Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891
    F O Smith
    T A Alonzo
    R B Gerbing
    W G Woods
    R J Arceci
    Leukemia, 2005, 19 : 2054 - 2062
  • [28] Children's Oncology Group blueprint for research: Acute lymphoblastic leukemia
    Raetz, Elizabeth A.
    Bhojwani, Deepa
    Devidas, Meenakshi
    Gore, Lia
    Rabin, Karen R.
    Tasian, Sarah K.
    Teachey, David T.
    Loh, Mignon L.
    PEDIATRIC BLOOD & CANCER, 2023, 70
  • [29] Family history of cancer and non-malignant diseases and risk of childhood acute lymphoblastic leukemia: A Children's Oncology Group Study
    Zierhut, Heather
    Linet, Martha S.
    Robison, Leslie L.
    Severson, Richard K.
    Spector, Logan
    CANCER EPIDEMIOLOGY, 2012, 36 (01) : 45 - 51
  • [30] The beneficial role of autologous bone marrow transplantation (ABMT) in the treatment of childhood acute myeloid leukemia (AML): A report from the Children's Cancer Group (CCG)
    Neudorf, S
    Sanders, JE
    Howells, W
    Gold, S
    Lange, BJ
    Kobrinsky, N
    DeSwarte, J
    Arthur, DC
    Barnard, D
    Dusenbery, KE
    Buckley, PJ
    Woods, WG
    BLOOD, 1998, 92 (10) : 294A - 294A